On Friday, Shares of Regions Financial Corp (NYSE:RF), lost -1.33% to $8.91.
Regions Bank, on Tuesday declared the launch of a new web channel dedicated exclusively to sharing information on the company’s culture.
Optimized for both desktop and mobile viewing, Regions.com/culture serves as a central location for articles, videos and personal stories describing how Regions conducts business and the company’s approach to community involvement and support.
“Culture is one of the most powerful forces in an organization, and we wanted to give people a better understanding of who we are,” said Rick Swagler, head of External Affairs for Regions Bank. “Our culture comprises commitments to customers, communities, shareholders and our associates, and this site brings those commitments to life with stories and videos that show our culture in action.”
Regions Financial Corporation is a financial holding company. The Company conducts its banking operations through Regions Bank, an Alabama state-chartered commercial bank, which is a member of the Federal Reserve System.
Shares of Mylan NV (NASDAQ:MYL), inclined 5.43% to $43.66, during its last trading session.
Mylan, declared the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen’s Invega®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia in adults and adolescents (12 – 17 years of age) in addition to schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults.
Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, had U.S. sales of about $606.2 million for the 12 months ending June 30, 2015, according to IMS Health.
Presently, Mylan has 260 ANDAs pending FDA approval representing $98.7 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
